Lowenstein Sandler represented Edesa Biotech (NASDAQ: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, in an exclusive collaboration and license agreement with leading Japanese pharmaceutical company KYORIN for the development and commercialization of paridiprubart, a first-in-class human monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses, in Japan.
Under the terms of the agreement, Kyorin obtained an exclusive license to further develop and commercialize paridiprubart for Acute Respiratory Distress Syndrome in Japan and Edesa received an upfront payment of $12 million and is eligible to receive additional development, regulatory and sales-based milestones of up to approximately $134 million, a portion of which is denominated in Japanese yen and double digit royalties.
The Lowenstein team included Michael J. Lerner, Tracy F. Buffer, and Victoria Jin.
